Cancer and COVID-19 - Authors' reply

Diagnostic procedures are challenging with COVID-19, autopsies are rare, and Vital Statistics Reporting Guidance specifically directs medical certifiers to list COVID-19 as the underlying cause of death, with the most immediate cause of death (eg, respiratory failure) listed first.2 Because this met...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet Vol. 396; no. 10257; pp. 1067 - 1068
Main Authors Kuderer, Nicole M, Wulff-Burchfield, Elizabeth, Rubinstein, Samuel M, Grivas, Petros, Warner, Jeremy L
Format Journal Article Web Resource
LanguageEnglish
Published England Elsevier Limited 10.10.2020
Elsevier BV
Elsevier Ltd
Subjects
Autopsies
Betacoronavirus
Cancer
Cohort Studies
Coronavirus Infections
Coronaviruses
Correspondence
COVID-19
Diagnostic systems
Genetics
Hematology
Humans
Laboratories
Malignancy
Medical research
Medical screening
Mortality
Neoplasms
Oncology
Pandemics
Pneumonia, Viral
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vital statistics
Online AccessGet full text

Cover

More Information
Summary:Diagnostic procedures are challenging with COVID-19, autopsies are rare, and Vital Statistics Reporting Guidance specifically directs medical certifiers to list COVID-19 as the underlying cause of death, with the most immediate cause of death (eg, respiratory failure) listed first.2 Because this method might overestimate COVID-19-related deaths, we reported all-cause mortality. Subsequent studies have shown a high risk of severe COVID-19 outcomes for patients with haematological malignancies.4,5 Despite a larger sample size, these analyses still do not have the power to identify, at the granular level, associations between the clinical status of the haematological malignancy, therapeutic modalities, and outcomes. PG reports consulting for AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Driver, EMD Serono, Exelixis, Foundation Medicine, GlaxoSmithKline, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck, Mirati Therapeutics, Pfizer, Roche, Seattle Genetics, and QED Therapeutics; participation in an educational programme for Bristol-Myers Squibb; and institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, Genentech, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Oncogenex, Pfizer, QED Therapeutics, and GlaxoSmithKline.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(20)32065-1